Jul. 31 at 1:50 AM
$BCLI
Peter Pitts only gets paid if Nurown in ALS and Exosome platform is successful!!!
On July 24, 2026, the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) appointed Peter Pitts, a member of the Board, as Executive Chairman
of the Board and Chief Strategic Regulatory Officer. In connection with his appointment, Mr. Pitts and the Company entered
into an offer letter dated July 24, 2026 (the “Offer Letter”), which provides a stock
option grant to purchase 900,000
shares of the Company’s common stock (the “Pitts Stock Option”), as evidenced by a Stock Option Grant Notice of the same date, and he will not be eligible to receive any base salary or cash bonus or participate in the director compensation program. The Pitts Stock Option generally vests with respect to one-fourth of the total shares on July 24, 2027, with the remaining shares vesting
in equal monthly installments over the next
three years.
